OpenAI to Continue Collaboration with Scale AI Despite Meta’s Major Stake Purchase

/in /tarafından

OpenAI confirmed it will maintain its partnership with Scale AI after Meta agreed to acquire a 49% stake in the AI data-labeling startup for $14.8 billion, OpenAI CFO Sarah Friar said at the VivaTech conference in Paris.

Scale AI is vital for providing the vast volumes of labeled training data essential for advanced AI tools like OpenAI’s ChatGPT. Despite Meta’s significant investment, OpenAI emphasized it intends to keep working with multiple data vendors rather than exclusively relying on Scale.

Friar highlighted the importance of keeping the AI ecosystem open, cautioning against moves that could slow innovation by locking out competitors. “We don’t want to ice the ecosystem because acquisitions are going to happen,” she said.

Meta’s stake comes as OpenAI’s ChatGPT competes directly with Meta’s Llama AI models. Scale AI’s CEO Alexandr Wang will now lead Meta’s new superintelligence unit, underscoring the startup’s growing influence in the AI space.

Friar also noted the increasing complexity of AI models requires input from a diverse network of human trainers with deep expertise—from academics to scientists—reflecting the growing sophistication in AI development.

Google’s $32 Billion Acquisition of Wiz Faces U.S. Antitrust Review, Bloomberg Reports

/in /tarafından

The U.S. Justice Department is reviewing Google’s planned $32 billion acquisition of cybersecurity firm Wiz to determine if the deal could unlawfully reduce competition in the marketplace, according to Bloomberg News citing sources familiar with the matter.

This acquisition would be Alphabet’s largest to date and aims to integrate Wiz into Google’s cloud division, bolstering its cybersecurity offerings for enterprise customers to manage critical risks.

Both Google and the DOJ declined to comment, and Wiz did not immediately respond to Reuters’ request. The deal reportedly gained momentum after President Donald Trump’s inauguration, amid expectations of a more favorable antitrust environment.

Executives at Wiz reportedly remained cautious following the collapse of Adobe’s $20 billion attempt to buy Figma due to antitrust challenges in late 2023. Google has agreed to pay Wiz over $3.2 billion if the deal fails to close.

Trump’s appointments of Andrew Ferguson as FTC chair and Gail Slater to oversee DOJ antitrust reviews reportedly increased confidence in a smoother regulatory process.

This scrutiny arrives as Google also faces ongoing DOJ lawsuits alleging monopoly abuses in online search and advertising technology markets. In April, a U.S. judge ruled Google liable for “willfully acquiring and maintaining monopoly power” in publisher ad servers and ad exchange markets.

AstraZeneca Signs $5.3 Billion AI Research Deal with China’s CSPC to Develop Chronic Disease Therapies

/in /tarafından

AstraZeneca has entered into a significant AI-driven research partnership with China’s CSPC Pharmaceutical Group worth up to $5.3 billion. The agreement aims to advance the development of therapies targeting chronic diseases, reinforcing AstraZeneca’s commitment to innovation in its second-largest market.

Under the collaboration, CSPC will conduct AI-led research in Shijiazhuang City to discover and develop pre-clinical candidates, including a small molecule oral therapy for immunological diseases. AstraZeneca will pay CSPC an initial upfront fee of $110 million and can receive up to $1.62 billion in development milestone payments, plus an additional $3.6 billion tied to sales milestones.

This partnership follows AstraZeneca’s broader efforts to strengthen its presence in China, including a $2.5 billion investment in a new R&D hub in Beijing announced earlier this year. It also builds on recent collaborations with AI-focused companies like Immunai, Qure.ai, and Tempus AI.

The deal also grants AstraZeneca rights to exclusive licenses for drug candidates identified through the joint research. This adds to a previous licensing deal signed in October, where AstraZeneca agreed to pay up to $1.92 billion to CSPC to enhance its cardiovascular drug pipeline.

CSPC, which derives about 80% of its revenue from finished drugs, is currently exploring additional licensing and collaboration opportunities, according to Morningstar analysts.

Sharon Barr, AstraZeneca executive, highlighted the collaboration as part of the company’s commitment to tackling chronic diseases affecting over two billion people worldwide.